Market Report Source

Overview

The world-wide market for Psoriasis therapeutics is estimated to be valued at $1-$3 billion annually. There are currently only 3 biologic competitors vying for share of this market. The Anti-TNF-a monoclonal antibodies—Enbrel, Humira, and Remicade—currently dominate the moderate-to-severe psoriasis therapeutic market. However, companies are aggressively developing both novel and second-generation compounds that have the potential to challenge the competitive position of these market leaders in the future. Potential threats on the horizon include biologic therapies such as Cimzia, CNTO-1275, Golimumab, and ABT-874 in both psoriasis and/or psoriatic arthritis. Additionally, the development landscape for small molecules could produce competitive therapeutic alternatives to Anti-TNFs. Novel compounds including BMS-582949 and Apremilast have a convenience and cost advantage over the biologics due to their oral formulation and potential attractiveness to managed care organizations and pharmacy benefit managers (payers). However it is yet to be seen if these agents will be able to demonstrate superior efficacy over the current market leaders.

The Psoriasis Therapeutic Clinical Intelligence report provides an in-depth assessment of the R&D competitive landscape for psoriasis (PsO)—from a clinical perspective. Additionally, the analysis highlights select compounds in the pipeline for Psoriatic Arthritis (PsA). The scope of the report focuses on competitive biologic and novel small molecule products in development and specifically captures key data on clincial trial design and data results for the products that have the potential to alter the market dynamics in psoriasis over the next 3-7 years.

This methodological approach is intended to provide insight into the strategic opportunities and challenges, as well as the clinical hurdles facing PsO/PsA drug developers.

Clients utilize the report as a resource to support key decisions including:

• Analyzing the overall depth and breadth of the competitive landscape within a therapeutic area
• Assessing target product profiles of key current and future competitors
• Benchmarking competitor clinical trial designs and results
• Developing clinical analogues to support go-no-go decisions
• Identifying clinical hurdles posed by competitors
• Designing clinical trials more effectively to maximize a product’s penetration

Reports contain synthesized information and analysis of clinical development activities for key marketed and pipeline products within multiple therapeutic categories and generally include the following data points:

Product Overview: Mechanism of Action, Developing Companies, Indications and Phase of Development.
Clinical Trial Assessments: Detailed evaluations of completed and ongoing competitor studies that capture key elements of the study protocol including:

• Trial design
• Start and end dates
• Study size and patient type
• Number of participating sites
• Dosing regimen
• Endpoints
• Safety and efficacy results

Table of Contents

Section 1: Executive Summary
Psoriasis Disease Overview
Classification of Psoriasis
Disease Epidemiology: U.S. & European Prevalence
Disease Epidemiology-Patient Segmentation
Psoriasis Treatment Paradigm
Conventional Psoriasis Therapies
Overview of Competitive Landscape
Ongoing Psoriasis Clinical Trials

Section 2: The Current Market Leaders in Psoriasis
Enbrel (etanercept)
Remicade (infliximab)
Humira (adalimumab)
Raptiva

Section 3: Future Competitive Threats
CNTO-1275
Golimumab (CNTO-148)
ABT-874
Cimzia
Zanolimumab

Section 4: Early Stage Development Programs: Products on the Radar
BMS-582949
Apremilast
BIRT 2584XX
AMG-714
BCX-4208
MEDI-545

Section 5: Appendix
Disclaimer
Report Licensing